The American Diabetes Association’s 86th Scientific Sessions wrapped last week in New Orleans, and the loudest headline came from Pfizer’s phase 2b VESPER-2 trial of berobenatide, a once-weekly and once-monthly GLP-1 showing a 2.2% A1c reduction and double-digit weight loss in people with Type 2 diabetes — with no plateau in sight.
It’s a real result. And it deserves more than a victory lap.
What Pfizer Actually Reported
In VESPER-2, 133 adults with overweight or obesity and Type 2 diabetes were randomized to berobenatide or placebo for 28 weeks. The highest dose cut A1c by up to 2.2% and body weight by up to 10.2%. The weight-loss curve was still trending downward at week 28. No new safety signals were flagged, and roughly 88% of treated participants had mild or no GI side effects — a notable tolerability win for the class.
A companion VESPER-3 trial tested a switch from weekly to monthly dosing in people without diabetes and saw up to 12.3% placebo-adjusted weight loss at the 4.8 mg monthly dose. An extension arm of VESPER-1 reported roughly 15.9% non-placebo-adjusted weight loss at 32 weeks on 2.4 mg weekly, again with no plateau.
This is the strongest ultra-long-acting GLP-1 data we’ve seen on a phase 2b stage.
What the Numbers Actually Mean for You
If you start berobenatide and respond like the average patient in the trial, your A1c lands somewhere between 1.5% and 2.2% lower, and you lose between roughly 8% and 16% of your body weight while you stay on the drug.
That is genuinely good news for blood sugar control. The drug works. Big pharma deserves credit. Mainstream tools like metformin, insulin, and the existing GLP-1 class have moved millions of A1c points and saved lives.
But the press release skips the only question that actually matters: What happens when you stop?
The Question Nobody’s Asking
Every GLP-1 data dump ends the same way — with a graph going up and to the right while the drug is in your system. Berobenatide is no different. The trial stops at 28 or 32 weeks. There is no “off-drug” arm showing sustained A1c reduction, no follow-up demonstrating that participants kept the weight off or held a normal A1c six months after their last injection.
That isn’t an accident. It’s the business model. A Type 2 diabetes patient who reverses their disease and walks off medication is a customer who doesn’t exist. A patient who stays on a monthly GLP-1 forever is recurring revenue.
The insulin resistance, the metabolic dysfunction, the fatty liver, the inflammation — those are still there the moment the dose wears off. The drug managed the symptom. It didn’t fix the cause.
The Bottom Line
Berobenatide is impressive science. It will likely become another option in a crowded field. If you choose it, you should choose it with your eyes open: the data shows you what happens while you take it. It tells you nothing about what happens after you stop.
Reversal is a different question with a different answer.
By:
Dr. Jeffrey Hockings / Co-Founder/CEO / Diabetes Reversal Group
Kristine Burke, MD / Chief Medical Officer / Diabetes Reversal Group